[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Citations 0
February 11, 2009

Omitted Financial Disclosure in: Testing for Fragile X Gene Mutations Throughout the Life Span

JAMA. 2009;301(6):602. doi:10.1001/jama.2009.78

Omitted Financial Disclosure: In the Commentary entitled “Testing for Fragile X Gene Mutations Throughout the Life Span” published in the November 26, 2008, issue of JAMA (2008;300[20]:2419-2421), there was an omission in the Financial Disclosures statement. On page 2421, the following text should be added at the end of the Financial Disclosures section, “Dr. P. Hagerman reported being listed as a coinventor in a US Government Provisional Patent Application (Published Patent Application No. 20080113355, filed in 2006) that reports a screening method for detecting expanded CGG repeats; and having a collaborative arrangement with Asuragen relevant to fragile X screening, for which he does not receive any financial compensation.”